Opioids and DOT Drug Testing: What the Federal Rules Say
Millions of CDL drivers take prescription opioids legally. That does not mean a DOT drug test will automatically come back negative. Here is exactly how federal law handles opioid positives, what the §40.137 MRO review process requires, what Suboxone does and does not show up as, and the one thing every collector must understand about medication disclosures.
Cedar & Crown Collector Academy · DOT Drug Testing
Quick Answer
The DOT 5-panel test includes an opioids panel covering morphine, codeine, heroin, hydrocodone, hydromorphone, oxycodone, and oxymorphone. Unlike marijuana — where the MRO has zero discretion — a valid prescription for opioids can result in the MRO cancelling a positive under 49 CFR §40.137. But even a cancelled result does not guarantee employment in a safety-sensitive position. For a full breakdown of all possible DOT test outcomes, see our guide to reading DOT drug test results.
The DOT 5-Panel Test: Where Opioids Fit
The standard DOT urine drug test screens for five substance categories under 49 CFR Part 40. Panel 4 covers opioids — the most clinically complex panel on the test because it includes both illicit drugs (heroin) and legitimately prescribed medications (oxycodone, hydrocodone, and others). This is what creates the need for the §40.137 MRO review process that does not exist for marijuana.
| Panel | Substance | Initial Screen Cutoff | GC/MS Confirmation |
|---|---|---|---|
| 1 | Cocaine (COC) | 150 ng/mL | 100 ng/mL |
| 2 | Amphetamines (AMP/MAMP) | 500 ng/mL | 250 ng/mL |
| 3 | Marijuana / THC (THCA) | 50 ng/mL | 15 ng/mL |
| 4 | Opioids (OPI/OXY/HER)opioids | 300–2,000 ng/mL | 10–2,000 ng/mL |
| 5 | Phencyclidine (PCP) | 25 ng/mL | 25 ng/mL |
The opioids panel is not a single cutoff — it covers seven distinct analytes, each with its own confirmation threshold. Here is the full breakdown per 49 CFR Part 40, Subpart F:
Panel 4 — Opioids: Full Cutoff Breakdown
| Analyte | Initial Immunoassay | GC/MS Confirmation |
|---|---|---|
| Morphine | 2,000 ng/mL | 2,000 ng/mL |
| Codeine | 2,000 ng/mL | 2,000 ng/mL |
| Heroin (6-AM) | 2,000 ng/mL (opiate screen) | 10 ng/mL |
| Hydrocodone | 300 ng/mL | 300 ng/mL |
| Hydromorphone | 300 ng/mL | 300 ng/mL |
| Oxycodone | 100 ng/mL | 100 ng/mL |
| Oxymorphone | 100 ng/mL | 100 ng/mL |
Note the 6-AM (6-acetylmorphine, the heroin metabolite) confirmation cutoff of 10 ng/mL — far lower than other opioids. This is intentional: a result above 10 ng/mL on 6-AM is definitive evidence of heroin use that cannot be explained by a legitimate prescription, because 6-AM is a direct heroin metabolite not produced by any other opioid.
The §40.137 MRO Rule: How a Valid Prescription Can Cancel a Positive
This is the most important distinction between opioids and marijuana in DOT testing. Under 49 CFR §40.85 (marijuana), the MRO has zero discretion — a positive is a positive regardless of any state authorization. But under 49 CFR §40.137, for opioids and other substances with legitimate medical uses, the MRO is required to give the donor an opportunity to provide a legitimate medical explanation before verifying the result as positive.
Here is how the process works step by step:
Laboratory reports non-negative result
The SAMHSA-certified laboratory confirms a positive opioid result via GC/MS and reports it to the MRO. The donor and employer are not notified at this stage.
MRO contacts the donor within 3 business days
The MRO must attempt to reach the donor using the contact information on the CCF. If the donor does not respond, the MRO makes a second attempt. If the donor still cannot be reached, the MRO may verify the result as positive or arrange for the DER to locate the donor.
Donor has 72 hours to provide prescription documentation
The donor must present a valid prescription from a treating physician — not a pharmacy printout, not a patient portal summary. The prescription must be from a licensed practitioner who is authorized under federal law to prescribe that controlled substance.
MRO verifies directly with the prescribing physician
The MRO does not simply take the donor's word for it. Under §40.137(f), the MRO must verify the prescription by contacting the prescribing physician — not just the pharmacy. The physician must confirm the prescription is legitimate, current, and was prescribed for that patient.
MRO cancels or confirms the result
If the prescription is valid and the drug level is consistent with therapeutic use, the MRO may cancel the positive and report the result to the employer as Negative. If no valid prescription is verified — or if the MRO determines the drug level is inconsistent with therapeutic use — the result is reported as Positive.
A cancelled result is not a clean slate for employers.
Even when the MRO cancels a positive and reports it as Negative, this does not bind the employer. Under FMCSA §382.213, employers may implement their own policy regarding employees who are using Schedule II–V controlled substances — including fitness-for-duty evaluations. A driver on a high-dose Schedule II opioid may be medically cleared for the prescription but still not fit to operate a 40-ton commercial motor vehicle.
Will Suboxone Show Up on a DOT Drug Test?
This is the most-searched opioid question in the DOT testing space — and the answer surprises most people.
No — Suboxone does not appear on the standard DOT 5-panel test.
Suboxone is a brand-name combination drug containing buprenorphine (a partial opioid agonist) and naloxone. Buprenorphine is not included in the DOT opioids panel. The standard immunoassay screens for morphine, codeine, heroin (6-AM), hydrocodone, hydromorphone, oxycodone, and oxymorphone — not buprenorphine. A standard DOT-compliant urine test will not flag Suboxone.
That said, there are three important caveats every CDL driver and employer should understand:
1. Expanded panels may detect it
Some employers require non-DOT drug testing as part of their own occupational health or safety program — often including an expanded panel that adds substances not covered by the federal 5-panel test. If an employer's non-DOT panel includes buprenorphine, Suboxone use would be detected. This varies entirely by employer policy.
2. FMCSA §382.213 still applies
Under 49 CFR §382.213, FMCSA-regulated employers can implement their own policy governing employees who use Schedule III–V controlled substances — even substances that are not on the DOT test panel. Buprenorphine (Suboxone) is a Schedule III controlled substance. An employer can require disclosure and a fitness-for-duty evaluation even if the DOT test would never flag it.
3. Disclosure to the employer's medical program is the practical advice
A CDL driver on Suboxone will not fail a DOT test based on buprenorphine. But the employment consequences depend on the employer's internal policy — and that policy may require disclosure. Drivers on Suboxone should consult with their employer's designated employer representative (DER) or occupational physician before a testing event, not after.
What DOT Collectors Must (and Must NOT) Do When a Donor Mentions Their Prescription
This is the section that matters most if you are a collector or training to become one.
It is extremely common for donors to mention their prescription during a collection. “I'm on oxycodone,” “I take hydrocodone for my back,” “my doctor knows I'm here.” The collector's response must be the same every time: acknowledge, proceed with the standard protocol, and document nothing about medication disclosures.
Under 49 CFR §40.69, the collector's job is to collect the specimen. Medication disclosure happens in the MRO interview under §40.137 — not at the collection site. Recording a donor's drug disclosures on the CCF or in collection notes is a chain of custody error that can compromise the specimen and expose both the collector and the employer to liability.
❌ What a collector must NOT do
- Record the donor's medication disclosure anywhere on the CCF or in collection notes
- Reassure the donor that their prescription will “explain” the result or that they “probably don't need to worry”
- Ask the donor what medications they are taking or why
- Delay or modify the collection procedure based on the donor's statements about prescriptions
- Express any opinion about whether the result will be positive or negative
- Advise the donor on how to handle the MRO interview
✓ What a collector must do
- Execute the standard collection protocol under §40.33 exactly as trained
- Document only observable facts on the CCF: specimen volume, temperature, collection time, any observable irregularities
- Complete the CCF accurately and completely with no extra annotations
- Seal and label the specimen correctly using tamper-evident materials
- Maintain the chain of custody without deviation
Common collector error: documenting drug disclosures on the CCF
Adding a note like “donor states they are on oxycodone” to the CCF remarks field may seem helpful — but it is a violation of proper collection procedure. The CCF is a chain of custody document, not a medical record. Notes like this can create the appearance that the collector reviewed or pre-screened the specimen and may cause the MRO or laboratory to question the integrity of the collection. Leave the remarks field clean unless documenting an actual collection irregularity per §40.69.
What Happens If the MRO Reports a Verified Positive Opioid Result
If the donor does not provide a valid prescription, or if the MRO determines no legitimate medical explanation exists, the result is reported as Positive to the employer. The federally mandated consequence sequence is identical to any other DOT positive:
Immediate removal from safety-sensitive function
The moment the MRO reports the verified positive to the employer's Designated Employer Representative (DER), the driver must be removed from safety-sensitive duty immediately. This is not discretionary. The driver cannot operate a commercial motor vehicle.
SAP (Substance Abuse Professional) evaluation
The driver must be referred to a Substance Abuse Professional for a clinical evaluation. The SAP determines what education or treatment is required before the driver may be eligible to return to duty. No driver can return to safety-sensitive functions without completing the SAP's recommended program.
FMCSA Clearinghouse entry
The verified positive is entered into the FMCSA Drug and Alcohol Clearinghouse. Any prospective employer who runs a pre-employment query will see the violation. The entry remains until the driver completes the full RTD process and the SAP files a return-to-duty report.
Return-to-Duty (RTD) process with observed collection
After completing the SAP's recommended program, the driver must pass a Return-to-Duty drug test. Critically, the RTD collection must be observed (§40.67) — a same-sex trained observer must directly observe the specimen provide. This is not the standard non-observed collection protocol. See our full Return-to-Duty process guide.
Follow-up testing schedule
Under §40.307, the driver must complete a SAP-directed follow-up testing program: a minimum of 6 unannounced observed tests over 12 months, extending up to 60 months. All follow-up collections are observed. The SAP sets the schedule; the employer's DER manages implementation.
Know exactly what to do when a donor mentions their prescription.
Certified collectors don't improvise. Cedar & Crown's $99 course covers every substance on the DOT panel, the §40.137 MRO review process, what belongs on the CCF, and the precise moment your role ends and the MRO's begins.
Enroll for $99 →What Employers Need to Understand About Prescription Opioids
The §40.137 MRO process puts employers in a position many are unprepared for: a driver whose test was positive comes back with a cancelled result and expects to return to the wheel. Understanding where employer authority begins — and where federal minimum requirements end — is essential for trucking HR, safety directors, and DERs.
The FMCSA §382.213 Employer Authority
Even after an MRO cancels a positive opioid result, FMCSA §382.213 preserves the employer's right to:
- Require a fitness-for-duty evaluation by a licensed medical professional before the driver returns to safety-sensitive functions
- Implement company policy requiring disclosure of Schedule II–V controlled substance use
- Consult with the MRO regarding whether, in the MRO's medical judgment, the driver's opioid use poses a safety risk
- Restrict the driver from safety-sensitive functions pending the fitness-for-duty determination
The public safety bar is higher for CMV operators.
A valid prescription for oxycodone is medically appropriate for millions of Americans. That same prescription in the hands of a driver operating an 80,000-pound commercial motor vehicle is a different risk calculus. Employers are not required by federal law to automatically restore safety-sensitive duties when a prescription explains a DOT positive — and best practice is to have a written policy addressing this before a positive ever occurs.
Employers who rely solely on the DOT test result without a separate prescription opioid policy are creating a gap in their safety program. The DOT test tells you what is in the specimen. It does not tell you whether that driver is safe to operate a CMV at the time of a given shift.
Frequently Asked Questions
Does a valid prescription guarantee a negative DOT drug test result?+
No — not automatically. Under 49 CFR §40.137, the MRO contacts the donor after a non-negative opioid result and asks whether there is a legitimate medical explanation. If the donor provides a valid prescription from a treating physician and the MRO verifies it directly with that physician — and the drug level is consistent with therapeutic use — the MRO may cancel the result and report it as Negative. But even a cancelled result does not guarantee the driver keeps their safety-sensitive position. Under FMCSA §382.213, employers retain the right to conduct a fitness-for-duty evaluation for drivers on Schedule II opioids.
Will Suboxone show up on a standard DOT drug test?+
No. Suboxone (buprenorphine + naloxone) is not included in the standard DOT 5-panel urine test. The DOT opioids panel tests for morphine, codeine, heroin (6-AM), hydrocodone, hydromorphone, oxycodone, and oxymorphone — not buprenorphine. A standard DOT-only test will not flag Suboxone. However, if an employer uses an expanded non-DOT panel (which some do as part of their own safety policy), buprenorphine may be detected. Under FMCSA §382.213, employers also have the right to implement their own policies around employees who are prescribed Schedule III–V controlled substances — even if those substances are not on the DOT panel.
What should a CDL driver do if they are taking prescription opioids?+
Do not attempt to hide the prescription or preemptively explain it to the collector — that is not the collector's role. If you test positive, the MRO will contact you within 3 business days of the non-negative result. At that point, you have 72 hours to provide documentation of your prescription from a treating physician. The MRO will verify directly with the prescribing doctor. Separately, you should consult your employer's DER or occupational health program about whether your employer has a fitness-for-duty policy for employees on Schedule II controlled substances — even if the MRO ultimately cancels the result.
What is the §40.137 MRO interview process for opioids?+
Under 49 CFR §40.137, when a SAMHSA-certified laboratory reports a non-negative opioid result, the MRO must attempt to contact the donor within 3 business days using the contact information on the CCF. If the donor does not respond, the MRO makes a second attempt. Once reached, the donor has 72 hours to present a valid prescription from a treating physician — not just a pharmacy printout. The MRO then verifies directly with the prescribing physician that the prescription is valid, that it was legitimately prescribed, and that the drug level is consistent with therapeutic use. Only after this verification can the MRO cancel the result and report it as Negative. If no valid prescription is verified, the MRO reports the result as Positive.
Can an employer remove a driver from duty even if the MRO cancelled the opioid result?+
Yes. A cancelled DOT result means the driver does not have a DOT violation — but it does not guarantee their fitness to perform safety-sensitive functions. Under FMCSA §382.213, employers have the authority to implement their own policy regarding employees who use Schedule III–V controlled substances, including prescription opioids. Drivers operating commercial motor vehicles have a higher safety bar, and a valid prescription for an opioid does not automatically mean the driver is fit to operate a CMV. Many employers require a separate fitness-for-duty evaluation from a licensed medical professional before allowing a driver on a Schedule II opioid to return to safety-sensitive duties.
Related Resources
Ready to Get Certified?
Cedar & Crown DOT Collector Course — six modules, bilingual, under a week, $99. Learn every substance on the DOT panel, the §40.137 MRO process, what to document and what to leave out, and exactly how to execute a compliant collection every time.
Enroll for $99 →